SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.

Abstract

Sunesis Pharmaceuticals Inc, under license from Dainippon Sumitomo Pharma Co Ltd, is developing SNS-595, a naphthyridine cell cycle inhibitor and apoptosis stimulator, for the potential treatment of a variety of solid and hematological malignancies. Phase I clinical trials had been completed in several solid tumor types and phase II clinical trials had been completed in patients with small-cell lung cancer and NSCLC. A phase II clinical trial in patients with platinum-resistant ovarian cancer and phase I/II and phase II clinical trials in patients with acute leukemias were ongoing at the time of publication.

• Authors: David A Mills, Houman M Fekrazad, Claire F Verschraegen
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 6 Pg. 647-57 (Jun 2008) ISSN: 1472-4472 [Print] England
• PMID: 18516764 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Naphthyridines
• Thiazoles
• vosaroxin

Topics

• Animals
• Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
• Apoptosis (drug effects)
• Cell Cycle (drug effects)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Contraindications
• Humans
• Naphthyridines (adverse effects, pharmacokinetics, therapeutic use)
• Neoplasms (drug therapy)
• Patents as Topic
• Randomized Controlled Trials as Topic
• Structure-Activity Relationship
• Thiazoles (adverse effects, pharmacokinetics, therapeutic use)